News >

Drake Discusses Immunomodulatory Therapies

Angelica Welch
Published: Friday, Aug 18, 2017

Charles Drake, MD, PhD

Charles Drake, MD, PhD
Finding a robust positive predictive biomarker for immunomodulatory drugs is difficult, says Charles Drake, MD, PhD, as the immune tumor microenvironment is so complex.

In an interview at the PER® 1st Annual International Congress on Oncology Pathology™, Drake, director of Genitourinary Oncology at NewYork-Presbyterian/Columbia University Medical Center and associate director for Clinical Research at the Herbert Irving Comprehensive Cancer Center, shared his insight on the promise and challenges with immunomodulatory drugs, and touched on immune-activating agents in prostate cancer.

OncLive: What therapies do you characterize as immunomodulatory?

Drake: That is a great question. Currently, when people talk about immunomodulatory therapies, most people think primarily of drugs that modulate immune checkpoints. Particularly, the antibodies that block the interaction between PD-1 and PD-L1. So, that is a series of 5 monoclonal antibodies that are FDA approved. The other immunomodulatory antibody blocks CTLA-4, that is called ipilimumab (Yervoy), and that is FDA approved in melanoma at the current time, but is being tested in combinations in other tumor types.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication